Whalesbook
The Debut Valuation
Accretion Nutraveda commenced trading on the BSE SME platform on February 4, 2026, at ₹191 per share. This marked a substantial 48% premium over its initial public offering (IPO) price of ₹129. The company's market debut established a valuation of ₹144.80 crore.
While a 48% listing gain is noteworthy, it fell slightly short of the unofficial grey market premiums. Prior to the listing, grey market estimates suggested gains ranging from 52.71% to 54.26% [cite: original input]. This suggests a subtle divergence between pre-listing speculative sentiment and the public market's actual valuation, indicating a degree of measured optimism rather than unrestrained exuberance.
Financial Foundation and Fund Deployment
The company's IPO, which garnered a 1.77 times subscription, will inject ₹24.77 crore of fresh capital. These funds are strategically allocated towards the acquisition of machinery to automate its existing manufacturing unit, bolstering working capital, and for general corporate purposes. This capital infusion aims to enhance operational efficiency and support the company's growth trajectory.
Financially, Accretion Nutraveda demonstrated robust growth. Revenue from operations surged from ₹5.01 crore in FY24 to ₹16.00 crore in FY25, a nearly 220% increase. Net profit followed suit, rising from ₹0.82 crore in FY24 to ₹2.61 crore in FY25, an increase of approximately 218%. The company reported a Return on Equity (ROE) of 48.85% on a trailing twelve-month basis. Post-IPO, the company's price-to-earnings (P/E) ratio stands at approximately 20.02x, a notable decrease from its pre-IPO P/E of 26.27x.
SME Market Context and Peer Performance
Accretion Nutraveda's listing occurs within a challenging yet active Indian SME IPO environment. In 2025, the average listing gain for SME IPOs dropped to 12.6%, the lowest since 2020, with over half of all listings trading below their IPO price by year-end. The BSE SME platform, where Accretion Nutraveda is listed, hosts nearly 700 companies with a combined market capitalization exceeding ₹1.82 lakh crore. While the pharmaceutical sector's industry P/E is around 43.1, Accretion Nutraveda's post-IPO P/E of 20.02x appears relatively attractive.
Outlook and Investor Sentiment
The company's impressive revenue and profit growth from FY23 to FY25, coupled with its expansion plans funded by the IPO, provide a foundation for future development. The successful listing, albeit tempered by grey market discrepancies, signals investor confidence in the contract manufacturing segment of the healthcare industry. The performance of Accretion Nutraveda will be closely watched as an indicator of investor appetite for growth-oriented companies within the broader SME market, which has shown a mixed return profile recently.